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Pulmonary arterial hypertension (PAH) develops in 7–12% of patients with systemic
sclerosis (SSc) and is associated with a 3 year survival of 52%. Early detection by
screening is therefore recommended for all patients with SSc. Historically, screening has
been performed using echocardiography andmeasurement of gas transfer. More recently
the DETECT protocol, using a combination of biomarkers (including N-terminal pro-brain
natriuretic peptide) and clinical parameters, has been developed. The optimal method
of screening for PAH with high sensitivity and specificity is, however, not clear. Protein
expression differences between different SSc disease phenotypes have been reported,
and include alterations in concentration of NT-proBNP, endoglin, soluble vascular
endothelial growth factor receptor 1, placenta growth factor, growth differentiation
factor-15, vascular endothelial growth factor alpha, resistin-like molecule beta, and
soluble thrombomodulin. This review summarizes the current knowledge of these protein
changes in patients with SSc and PAH.
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INTRODUCTION
Pulmonary arterial hypertension (PAH) is a rare disease characterized by a progressive
vasculopathy of the small pulmonary arteries leading to increased pulmonary vascular resistance
and right ventricular afterload. This results in right ventricular failure and premature death. PAH
may be idiopathic, heritable, related to various drugs and toxins ormay be associated with a number
of medical conditions including congenital systemic to pulmonary shunts, portal hypertension,
HIV and connective tissue disease, most notably systemic sclerosis (SSc). Although these forms
of PAH have similarities in underlying pathophysiology and treatment regime, it is increasingly
recognized that there are differences in pathobiology, response to treatment and prognosis.
Between 7 and 12% of patients with SSc develop PAH (SSc-PAH) at some point in their
disease course (1–4). Compared to idiopathic pulmonary arterial hypertension (IPAH), histological
patterns in SSc-PAH show greater intra-individual variability, a relative absence of plexiform
lesions, more prominence of intimal fibrosis and amuch greater involvement of pulmonary venules
(5). Prognosis is significantly worse than in other forms of PAH with median survival of 3 and 7.8
years in SSc-PAH and IPAH cohorts respectively (6). Response to treatment is generally felt to be
worse in SSc-PAH than in IPAH (7).
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The diagnosis of PAH can be challenging, due in part to the
relatively low incidence of this condition, and in part due to
the non-specific nature of the early symptoms. As a result, the
diagnosis of PAH is often made at an advanced stage after a large
proportion of the pulmonary vascular bed has been irreversibly
obliterated by pathological vascular remodeling.
Given the progressive nature of vascular remodeling in PAH,
interest in the outcome of patients detected early has led to
investigation of alternative screening methods in patients with
systemic sclerosis. It is thought that early diagnosis and treatment
leads to a favorable prognosis (8, 9). Historically, screening for
PAH in SSc has involved estimating systolic pulmonary arterial
pressure at annual echocardiography ± the measurement of
diffusion capacity of the lung for carbon monoxide (DLCO).
The DETECT protocol was developed to provide an evidence-
based multi-modality approach to screening patients with
SSc for the presence of PAH. It combines variables from
clinical examination, echocardiography, electrocardiography,
pulmonary function tests and blood tests [uric acid and
N-terminal pro-brain type natriuretic peptide (NT-proBNP)] to
produce a score with high sensitivity (95%), but relatively low
specificity (48%) for the presence of PAH (10). The DETECT
protocol involves several steps which add complexity and in
real-life clinical practice, may prove significantly more expensive
and can lead to delay and even failure to refer for definitive
investigations (11).
Abnormal concentrations of many candidate proteins have
been shown in both the tissue and circulating compartments in
patients with PAH. These proteins may reflect the underlying
pulmonary vascular disease as well as the response of the right
ventricle to the increased afterload. They may also reflect the
underlying SSc rather than PAH. It is conceivable that a panel
of protein biomarkers may have utility in identifying PAH in
still asymptomatic patients with systemic sclerosis. This paper
reviews the current published evidence base for altered protein
biomarker concentrations in SSc-PAH.
METHODS
To identify suitable primary research articles on this topic,
a literature search was conducted using Ovid Medline
and PubMed. Keywords used were “Systemic sclerosis,”
“Scleroderma,” “Pulmonary hypertension,” “PAH,” “Protein,”
and “Biomarker.” Date of publication was limited from 1990
to present day. One hundred and forty eight publications were
returned from this search.
We included studies identifying a cohort of patients diagnosed
with systemic sclerosis with PAH with comparator groups
including healthy volunteers (HV), systemic sclerosis without
pulmonary hypertension (SSc-no PAH) and/or idiopathic PAH.
Studies were included if they reported data on differential
protein expression between subgroups which were related to
objective measurements of pulmonary hypertension.
Protein Biomarkers in SSc-PAH
The circulating protein biomarkers identified by the literature
search are summarized in Table 1 and Figure 1.
N-Terminal Pro-Brain Natriuretic Peptide
(NT-proBNP)
NT-proBNP is a marker of myocardial stress and therefore
a non-specific marker for pulmonary hypertension (PH).
Brain type natriuretic peptide (BNP) and NT-proBNP
remain the only blood-based biomarkers suggested by
guidelines for routine clinical use (21). NT-proBNP is an
inactive cleavage product released during the activation of
BNP from its prohormone. BNP is released in response to
ventricular stretch and stimulates natriuresis and diuresis
via the kidney in order to reduce ventricular preload. NT-
proBNP is elevated in PH of any cause (22) and correlates with
echocardiographic, hemodynamic and functional measurements
(23–25).
NT-proBNP may be elevated in systemic sclerosis in the
absence of pulmonary hypertension as a result of left ventricular
disease and primary myocardial involvement (26).
In a prospective observational study of 109 patients with
systemic sclerosis, including 68 with PH and 41 without PH
at right heart catheter, Williams et al. set out to evaluate
the utility of NT-proBNP concentrations as a screening tool
for PAH. NT-proBNP concentration was significantly higher
in patients with PAH than without (1474 pg/ml vs. 139
pg/ml respectively, p = 0.0002). The authors also reported a
significant correlation between NT-proBNP concentration and
mean pulmonary arterial pressure (mPAP) (r= 0.62, p< 0.0001),
pulmonary vascular resistance (PVR) (r = 0.81, p < 0.0001)
and right atrial pressure (RAP) (r = 0.53, p < 0.0001) at
right heart catheterization (RHC). For the ability to accurately
diagnose PAH a threshold of 395 pg/ml was selected, returning
a sensitivity 55.9%, specificity 95.1%, PPV 95.1% and NPV
56.5%. Longitudinal analysis of baseline and change in serial NT-
proBNPmeasurements both demonstrated significant prognostic
utility (27). More recent work has provided validation, with
Chung et al. reporting a sensitivity and specificity of 73 and 78%
respectively for NT-proBNP at a threshold of 210 pg/ml, slightly
superior to that of BNP at 71 and 59% respectively at a threshold
concentration of 64 pg/ml (13).
Comparing between PAH phenotypes in a study of 98
prevalent PAH patients (SSc-PAH n = 55; IPAH n = 38;
Anorexigen n = 5), Mathai et al. found that NT-proBNP levels
were significantly higher in the SSc-PAH group vs. IPAH group
(1846 pg/ml vs. 808.5 pg/ml respectively, p < 0.01), and this was
despite a significantly higher mPAP in the patients with IPAH (41
mmHg vs. 48 mmHg, SSc vs. IPAH respectively, p < 0.01). The
authors also noted stronger correlations between NT-proBNP
concentrations and hemodynamic measures of PAH for patients
with SSc-PAH than for those with IPAH; cardiac index (CI)
(r = −0.58, p < 0.01 vs. r = −0.46, p < 0.01 respectively); PVR
(r = 0.54, p < 0.01 vs. r = 0.41, p < 0.01 respectively). When
serial protein measurements were analyzed in each subgroup, the
prognostic value of NT-proBNP for predicting death remained
only in the group with SSc-PAH (SSc-PAH: hazard ratio (HR)
3.07, p< 0.01; IPAH: HR 2.02, p= 0.29) (14).
The DETECT study investigated a population of SSc patients
who were enriched for the presence of PAH by the inclusion
of patients with a DLCO <60% predicted (10). NT-proBNP
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TABLE 1 | Summary of potential protein biomarkers in SSc-PAH.
Protein Comparison
Groups
Number of
Patients
Outcome Correlations in
SSc-PAH
Reference
NT-proBNP SSc-PAH vs. SSc
SSc-PAH vs. SSc
SSc-PAH vs. IPAH
109
329
98
Significantly higher in SSc-PAH vs. SSc. Sens
55.9%, Spec 95.1%. Correlated with invasive
hemodynamics
NT-proBNP superior to BNP for detection of
PAH in SSc
Significantly higher in SSc-PAH, correlated with
hemodynamics and predicted survival in
SSc-PAH group.
mPAP (r = 0.62;
p < 0.0001)
PVR (r = 0.81;
p < 0.0001)
CI (r = −0.58;
p < 0.01)
PVR (r = 0.54;
p < 0.01)
(12)
(13)
(14)
Endoglin SSc-PAH vs. SSc
vs. HV
60 Serum levels significantly higher in SSc-PAH
than control
(15)
sFLT-1 SSc-PAH vs. SSc 77 Plasma levels significantly higher in SSc-PAH
and correlate with RVSP and inversely with
DLCO. Possible predictor of PH progression.
RVSP (r = 0.32;
p = 0.01)
DLCO (−0.29;
p = 0.01)
(16)
PlGF SSc-PAH vs. SSc 77 Plasma levels significantly higher in SSc-PAH.
Correlates with severity of Raynaud’s
phenomenon and inversely with DLCO.
DLCO (r = −0.031;
p = 0.01)
(16)
VEGF-A SSC-PAH vs. SSc
vs. HV
53 Serum levels significantly higher in SSc-PAH
than either SSc or HV. Levels correlate with
echocardiographic sPAP, dyspnoea score and
DLCO.
sPAP (r = 0.58;
p < 0.01) DLCO
(r = −0.47; p < 0.01)
(17)
GDF-15 SSc-PAH vs. SSc 54 Plasma levels significantly higher in SSc-PAH,
correlate with echocardiographic RVSP and
circulating NT-proBNP. Discriminates between
PH and non-PH.
RVSP (r = 0.56;
p < 0.001)
(18)
RELM-ß SSc-PAH vs. IPAH
vs. HV
26 Tissue concentrations significantly higher in
SSc-PAH than in IPAH or HV.
(19)
sThrombomodulin SSc-PAH vs. SSc
vs. HV
92 Significantly higher plasma levels in SSc-PAH
compared to either SSc or HV.
(20)
NT-proBNP, N-terminal pro-brain type natriuretic protein; sFLT-1, soluble vascular endothelial growth factor receptor 1; PlGF, placenta growth factor; VEGF-A, vascular endothelial growth
factor A; GDF-15, growth differentiation factor-15; RELM-ß, resistin like molecule-ß; sThrombomodulin, soluble thrombomodulin; SSc-PAH, systemic sclerosis related pulmonary arterial
hypertension; SSc, systemic sclerosis; IPAH, idiopathic pulmonary arterial hypertension; HV, healthy volunteer; Sens, sensitivity; PH, pulmonary hypertension; Spec, specificity; mPAP,
mean pulmonary artery pressure; PVR, pulmonary vascular resistance; CI, cardiac index; RVSP, right ventricular systolic pressure; DLCO, diffusing capacity for carbon monoxide; sPAP,
systolic pulmonary artery pressure; EC, endothelial cells.
was included in a final 2-step algorithm which also included
electrocardiography and echocardiography to select patients to
proceed to RHC. Sensitivity for the detection of PAH was high
(96%) but specificity was only 48%.
Both BNP and NT-proBNP levels have been demonstrated to
be important prognostic predictors at baseline in PAH (28, 29).
Subsequently, the change in NT-proBNP level after therapy was
shown to be a powerful independent predictor of survival (30).
More recently three large studies have confirmed the importance
of changes in NT-proBNP in the risk stratification of patients
with PAH during follow-up. (12, 31, 32).
Endoglin
Transforming growth factor beta (TGF-ß) signaling has been
strongly implicated in the pathogenesis of PAH, and extensively
studied, particularly with regard to bone morphogenetic protein
receptor type-2 mutations (26). TGF-ß signaling regulates several
processes including cellular proliferation and angiogenesis.
Endoglin (Eng) is a transmembrane protein expressed in
endothelial cells which acts as a TGF-ß signaling complex
component (33).
Both TGF-ß serum concentration and Eng level are raised in
IPAH patients, with Eng localized to endothelial cells in tissue
samples (34). Germline Eng mutation have shown a protective
effect against the development of pulmonary hypertension in
heterozygous models exposed to chronic hypoxia (34).
Coral-Alvarado et al. investigated circulating Eng
concentration in 60 patients (20 SSc-PAH; 20 SSc-no PAH;
20 HV). PH was diagnosed by estimation of systolic pulmonary
artery pressure >35 mmHg, or tricuspid regurgitant jet velocity
>3 m/s. The authors report higher Eng concentrations in the
SSc-PAH group, however possibly due to small study numbers,
the difference is only statistically significant between SSc-PAH
vs. healthy volunteer (HV) groups (SSc-PAH: 6.89 ng/ml,
SSc-no PAH: 6.2 ng/ml, HV: 5.42 ng/ml; SSc-PAH vs. SSc-no
PAH p = 0.2447, SSc-PAH vs. HV p = 0.0006, SSc-no PAH
vs. HV p = 0.057). There was no correlation noted between
Eng concentration and echocardiographic measurements of
PH (15).
There is some evidence for altered Eng expression in PAH,
however in SSc specifically, this evidence is weak in part due
to small study sizes and study design. Given the potential role
of Eng in TGF-ß signaling, a role in the pathogenesis of PAH
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FIGURE 1 | Cellular origin and pathways for each protein described in the context of SSc-PAH. Description of the likely origin of each protein, along with the
pathophysiological process it has a role in. If a component of one of the pathways known to be relevant to pathogenesis of PAH then this is also given. SMC, vascular
smooth muscle cell; EC, vascular endothelial cell; RV, right ventricle; TGF-ß, transforming growth factor beta; VEGF, vascular endothelial growth factor; NT-proBNP,
N-terminal pro-brain natriuretic peptide; GDF-15, growth differentiation factor-15; RELM-ß, resistin-like molecule beta; VEGF-A, vascular endothelial growth factor A;
sFLT-1, soluble vascular endothelial growth factor receptor 1; PlGF, placenta growth factor; Eng, endoglin; sThrombomodulin, soluble thrombomodulin.
remains reasonable, however further work in this area is needed
to establish its role.
VEGF-A
Vascular Endothelial Growth Factor-A (VEGF-A) is a member
of the PDGF superfamily of growth factors. It is one of the
most potent regulators of angiogenesis, and acts on vascular
endothelial cells through stimulation of KDR (VEGF receptor 2)
and FLT-1 (VEGF receptor 1) to promote angiogenesis, increase
vascular permeability and stimulate endothelial cell migration
(35, 36).
Serum VEGF-A concentrations are known to be elevated in
patients with PAH and have been demonstrated within plexiform
lesions of remodeled vasculature (17, 37).
In a study including 53 participants (SSc-PAH n = 20,
SSc-no PAH n = 20, HV n = 13) Papaioannou et al.
examined the relationship of serum VEGF-A concentration to
echocardiographic markers of pulmonary hypertension. In this
study, participants were treatment naive, and any patients with
pulmonary fibrosis were excluded. Estimated sPAP >35 mmHg
was used to define patients with SSc-PAH. The authors found
significantly higher VEGF-A concentrations in all patients with
SSc as compared to HV (267 pg/ml vs. 192 pg/ml respectively,
p < 0.01), and further found that those with SSc-PAH had
higher levels than those with SSc-no PAH (352 pg/ml vs. 240
pg/ml respectively, p < 0.01). In patients with SSc, significant
correlations were found between serum VEGF-A concentration
and systolic pulmonary arterial pressure (sPAP) (r = 0.58,
p < 0.01); MRC dyspnoea score (r = 0.34, p = 0.031); and
DLco (r = −0.47, p < 0.01). In multivariate modeling of sPAP
as the dependent variable, VEGF-A concentration remained a
significant predictor when adjusted for age and gender (17).
VEGF-A expression is known to be upregulated in both
patients PAH, and with systemic sclerosis, both conditions
characterized by pathologically excessive endothelial activation.
In patients with SSc-PAH the VEGF pathway is upregulated,
however baseline levels have not been assessed for utility as
diagnostic biomarkers.
Placenta Growth Factor (PlGF) and Soluble
Vascular Endothelial Growth Factor (VEGF)
Receptor 1 (sFLT-1)
Placenta growth factor is a member of the vascular endothelial
growth factor family of proteins which binds with high
affinity for VEGF receptor 1 (FLT-1/ VEGF-R1), but not
for VEGF receptor 2 (KDR/ VEGFR2)—regarded as the
main effector protein of VEGF signaling (38). PlGF alone
does not stimulate tyrosine kinase phosphorylation or
proliferation in human endothelial cell lines, however
the addition of PlGF potentiates the effect of VEGF-A
in stimulating proliferation of cultured endothelial cells
(38).
sFLT-1 is a variant of VEGF receptor 1 (FLT-1) which can
bind VEGF-A, VEGF-B, and Placenta growth factor (PlGF). It
functions as a decoy receptor, downregulating free ligand and
therefore thought to control excessive endothelial activity (39).
Recognizing the need for further study into diagnostic
biomarkers for patients with SSc-PAH, McMahan et al. designed
a case-control study of 77 patients with SSc (37 with PH, 40
without PH). The groups were unbalanced for age (64.9 vs. 55.9
respectively, p < 0.01) and lung volumes (FVC% 67.5 vs. 88.1
respectively, p < 0.01). Diagnosis of PH was based on mPAP ≥
25 mmHg at right heart catheterization. The authors report that
both PlGF (24.8 pg/ml vs. 19.1 pg/ml, p= 0.02) and sFLT-1 (101.8
pg/ml vs. 89.7 pg/ml, p = 0.02) are significantly upregulated
in patients with PH that in those without. Both proteins were
significantly inversely correlated to DLco (PlGF: r = −0.31,
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p = 0.01 and sFLT-1: r = −0.29, p = 0.01). sFLT-1 was also
correlated to RVSP (r = 0.32, p= 0.01) (16).
This study was designed to evaluate potential biomarkers
of pulmonary hypertension in systemic sclerosis. No comment
is made about extent of pulmonary fibrosis, so it remains
conceivable that these are imbalanced given the difference in
baseline pulmonary function tests, and it is not clear why
no comparisons were given for protein concentration and
invasive right heart catheter measurements. Although protein
concentration changes are noted, no statistics have been given for
the performance of these proteins as diagnostic markers.
GDF-15
Growth Differentiation Factor-15 (GDF-15) is a member of the
TGF-ß superfamily of cytokines playing an important role in
cell growth and differentiation. It is a stress responsive cytokine
associated with tissue damage and inflammation. Increased levels
have been reported in heart failure, atherosclerosis, endothelial
dysfunction and diabetes and have been linked to disease
progression and prognosis (40).
In treatment naïve IPAH, serum GDF-15 is increased and is a
significant predictor of survival (41). In a mixed cohort of PAH
patients, tissue levels of GDF-15 are increased—localizing to the
pulmonary endothelium, and in remodeled vessels strong signals
are identified in plexiform lesions (42). In-vitro studies using
pulmonary endothelial cells and varying concentrations of GDF-
15 resulted in reduction in hypoxia induced apoptosis suggesting
a potential pathological mechanism in PAH (42).
Meadows et al. studied a cohort of 111 patients (SSc-PAH
n = 30, SSc-no PAH n = 24, IPAH n = 44, HV n = 13)
for circulating GDF-15 concentrations. PH was defined at right
heart catheterization. Patients with PAH were already established
on PH specific therapy at the time of entry to study. Both
plasma and tissue levels of GDF-15 were elevated in SSc-PAH
(442 pg/ml), and differentiated it from SSc without PAH (108
pg/ml, p = 0.0004), IPAH (173 pg/ml, p = 0.0003) and HV (66
pg/ml, p = 0.0013). Within the SSc subgroup, GDF-15 levels
correlated with echocardiographic RVSP (r = 0.556, p < 0.001),
and with NT-proBNP concentration (r = 0.484, p < 0.001),
but not with other invasive hemodynamics. On diagnostic ROC
analysis, GDF-15 has been shown to have good discriminative
power with area under curve (AUC) 0.91 for differentiation of
SSc-PAH from SSc without PH with an optimal threshold for
GDF-15 of 125 pg/ml demonstrating 93% sensitivity and 88%
specificity for the presence of SSc-PAH. Furthermore, patients
below this threshold were found to have significantly improved
survival (18).
Resistin-Like Molecule-ß (RELM-ß)
RELM-ß is a member of a relatively newly described resistin
family. Largely studied through their effects on animal models,
these proteins have been shown to induce angiogenesis and
vascular remodeling (19).
Following the identification that hypoxia induced mitogenic
factor(HIMF) is upregulated in animal models of PH, Angelini
et al. sought to evaluate this in human tissues. In a small study
involving 26 prevalent patients (SSc-PAH n = 9, IPAH n = 11,
HV n= 6), the authors found that in human lung tissue samples,
RELM-ß (a close human homolog to HIMF) is upregulated in
patients with SSc-PAH as compared to healthy control (p< 0.01,
measured by relative intensity on western blot) and localizes
to remodeled vasculature. In comparison, although some
expression of RELM-ß was noted in remodeled vessels of patients
with IPAH, this was inconsistent, and relative quantification
showed no difference between IPAH and HV concentrations.
Additional in-vitro study showed mitogenic activity of RELM-ß
on both human lung microvascular endothelial cells and human
pulmonary artery smooth muscle cells (19).
This is a relatively novel candidate protein, which appears
to show higher expression in SSc-PAH, however more work is
needed to assess its concentration in the circulating compartment
if it is to be considered further as a biomarker as lung tissue
samples are not practical for this purpose.
Soluble Thrombomodulin
(sThrombomodulin)
Thrombomodulin is a glycoprotein expressed on endothelial
cells. Its physiological function is to bind thrombin and alter its
activity, to subsequently activate protein C (15). The pathogenesis
of both systemic sclerosis and PAH involves and injury to and
activation of the vascular endothelium. Soluble thrombomodulin
is increased in conditions associated with endothelial damage
(43).
Stratton et al. studied 92 patients (SSc-PAH n = 34, SSc-no
PAH n = 38, HV n = 20) and found that sThrombomodulin
was increased plasma of patients with SSc-PAH (65.4 ng/ml)
compared to SSc without PH (43.3 ng/ml, p < 0.05), and healthy
controls (38.1 ng/ml, p < 0.05). There was no difference in
circulating concentration between SSc without PH and healthy
control (20). This is in contrast to previous studies which have
shown a significant decrease in circulating sThrombomodulin
concentration in patients with PAH (IPAH and PAH due to
Eisenmenger’s’ syndrome) compared to healthy controls (26 vs.
44 ng/ml respectively, p= 0.0001) (44).
DISCUSSION
A biomarker has been defined by the NIH as “a characteristic that
is objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention.” Strimbu, et al. (45)
NT-proBNP is the most widely studied circulating biomarker in
clinical use in patients with suspected or known PAH. Elevations
in NT-proBNP result from right ventricular (RV) strain as a result
of increased RV afterload. As it does not reflect the underlying
pathophysiology of the pulmonary arterial vasculopathy resulting
in increased RV afterload in PAH, NT-proBNP levels can be
elevated due to other pathophysiological processes including
increased RV afterload due to PH arising from left heart disease
and from disease processes directly affecting the myocardium.
As such, the specificity of NT-proBNP in the diagnosis of SSc-
PAH tends to be rather low resulting in a significant number
of RHCs being performed in patients who do not in the end
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have PAH (10). Furthermore, given the dismal prognosis in SSc-
PAH, identifying patients early in their disease process before the
development of RV strain is desirable (46, 47). The identification
of a biomarker or panel of biomarkers which more reflect the
underlying pulmonary vasculopathy in SSc-PAH prior to the
development of RV strain is therefore of interest.
The data described in the current manuscript summaries the
current evidence for various candidate circulating diagnostic
biomarkers for SSc-PAH, several of which do relate known
pathways known to be important in PAH pathogenesis, especially
the TGF-ß and VEGF pathways. Further study within well
phenotyped cohorts of patients to compare the performance of
these candidate circulating biomarkers against NT-proBNP and
the DETECT protocol are clearly warranted.
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